Company intelligence / Profile preview
STAb Therapeutics
Madrid, Community of Madrid, Spainstabtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has developed a next-generation cell immunotherapy platform where genetically engineered patient T cells secrete bispecific T-cell engagers in situ, redirecting both modified and unmodified bystander patient T cells to attack tumor-associated antigens. This approach aims to enhance immune redirection and persistence for the treatment of solid and hematological cancers. As of mid–2025, the company remains preclinical with no reported clinical trial results.
- Therapeutic areas
- OncologyHematology
- Modalities
- Cell therapy (engineered T cells)Bispecific antibodies (T cell engagers, TCEs)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
CRIS Cancer Foundation [support/funding partner]
Beyond the preview
Go deeper on STAb Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STAb Therapeutics.